GRAIL (NASDAQ:GRAL – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Profitability
This table compares GRAIL and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRAIL | -236.95% | -15.88% | -14.02% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Insider and Institutional Ownership
58.7% of Connect Biopharma shares are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
GRAIL has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for GRAIL and Connect Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRAIL | 1 | 6 | 5 | 0 | 2.33 |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
GRAIL currently has a consensus target price of $119.80, indicating a potential downside of 16.61%. Connect Biopharma has a consensus target price of $5.88, indicating a potential upside of 652.72%. Given Connect Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than GRAIL.
Valuation & Earnings
This table compares GRAIL and Connect Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GRAIL | $147.17 million | 43.60 | -$408.35 million | ($9.75) | -14.73 |
| Connect Biopharma | $60,000.00 | 819.13 | -$55.48 million | ($1.19) | -0.66 |
Connect Biopharma has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Connect Biopharma beats GRAIL on 9 of the 13 factors compared between the two stocks.
About GRAIL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
